Savient Pharmaceuticals, Inc. (NASDAQ: SVNT): After last week's success with their gout drug, these shares haven't stopped rising. They reached a new high of $21.36 against 52-week low of $10.58.

Trane Inc. (NYSE: TT): A nice big buy-out from Ingersoll-Rand Company Limited (NYSE: IR) sent shares up to $45.27 from 52-week low of $32.09.

Varian Medical Systems, Inc. (NYSE: VAR): The FDA approved new proton scanning product. The stock Traded up to $52.05 from 52-week low of $37.30.

Coca-Cola Enterprises Inc. (NYSE: CCE): Still moving up after last week's strong forecast. Hit $26.93, up from 52-week low of $18.78.

Douglas A. McIntyre is an editor at 247wallst.com.

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL): Sees good news on its rheumatoid arthritis drug. Jumps to $26.45 up from 52-week low of $6.64.

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT): Gets strong results from late stage trials for drug which effectively treated patients with gout. Shares move up to $18.58 from 52-week low of $10.58.

BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN): FDA approves company's new drug. Stock up to $30.49 and more after hours from 52-week low of $15.53.

Coca-Cola Enterprises Inc. (NYSE: CCE): Has a strong earnings outlook for next year. Moves up to $26.83 from 52-week low of $19.78.

PepsiCo, Inc. (NYSE: PEP): No news. Just a safe, successful place to put money. Up to $78.78 from 52-week low of $61.89.

Douglas A. McIntyre is an editor at 247wallst.com.

This year has been a stock picker's market extraordinaire! This month's review provides ample evidence of this, as you'll note that Google (NASDAQ: GOOG), which I included for fun because of its popularity, beat all else as a portfolio of one. The average of my seven picks came in second, beating James Cramer's average based on his nine picks. Both Cramer and I beat each of the three indices I am tracking, and therefore beat the average as well, with the largest and most stable, the Standard & Poor's 500 coming in last.

Of course, this could easily change given recent market volatility. A sharp downturn in the market could reverse our fortunes. A lot can happen in the remaining two months -- I take nothing for granted.

While Google shined brightly this year, Cramer and I have each made one pick that shined brighter. Cramer's best, Apple (NASDAQ: AAPL) has gone into orbit this year on the wings of the iPhone, iPod, and growing Mac sales. Benefiting from rising oil prices, shortages in China and the Chinese government allowing a 10% price hike, my PetroChina ADR (NYSE: PTR) has rocketed, becoming the second-largest capitalized company in the world. PTR has done this even in the shadow of Berkshire Hathaway (NYSE: BRK.A) selling its shares and Warren Buffett questioning the huge appreciation of the Chinese stock market and stocks overall.

Many traders review short interest for added insight each month. Interestingly enough, many traders bet against Jim Cramer picks and they do so with short selling. The truth is that just because a pundit of any size adds a large percentage gain to a stock, it actually doesn't change the fundamentals. It does however raise the interest in the issue.

So, we all know that many traders love to pick on Cramer. Here are some interesting points on Cramer's ongoing picks for 2007 and looking at the short selling trends from May to June (2007):

Level 3 Communications, Inc. (NASDAQ: LVLT) was Cramer's top speculative pick for the year: June short interest was 119.9 million shares, up 9.7% from the 109.3 million shares short in May.

Savient Pharmaceuticals (NASDAQ: SVNT) was Cramer's top speculative biotech pick this year: June short interest was 7.95 million, up 6.6% from 7.45 million shares short in May.

Nastech Pharmaceuticals (NASDAQ: NSTK) was another fairly recent Cramer biotech pick, which was a biotech zombie he thought would turn around: June short interest was 5.09 million shares, up 21% from the 4.2 million shares short in May.

As a reminder, short sellers often have many reasons for short selling. Sometimes it is a pure bet against a company, just as it would seem, other times it might be as a hedge in an upcoming event or a hedge for an options trade. But out of these, you know there have to be some of the shorts selling the stock just because they don't like the Cramer plays.

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.